Methotrexate resistance in human uroepithelial cells with p53 alterations

Journal of Urology

Volumn 159, Issue 2, 1998, Pages 581-585

  Yeager, Thomas R ^a   Reznikoff, Catherine A ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Human uroepithelial cells; Methotrexate resistance; p53 alterations

Indexed keywords

DIHYDROFOLATE REDUCTASE; METHOTREXATE; PROTEIN P16; PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GENETICS; CANCER RESISTANCE; CONTROLLED STUDY; DRUG UPTAKE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 0031964908     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63988-0     Document Type: Article

References (21)

1. American Cancer Society: Cancer Facts & Figures, 1996.
2. Thrasher, J. and Crawford, E. D.: Current management of invasive and metastatic transitional cell carcinoma of the bladder. J. Urol., 149: 957, 1993.
3. Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J. and Chabner, B. A.: The pharmacology and clinical use of methotrexate. N. Engl. J. Med., 309: 1094, 1983.
4. Bane, B. J., Rou, J. Y. and Hamstreet, G. P.: Pathology and staging of bladder cancer. Semin. Oncol., 23: 546, 1996.
5. Tu, Y. P., Xu, F. H., Liu, J., Vescio, R., Berenson, J., Fady, C. and Lichtenstein, A.: Upregulated expression of BCL-2 in multiple myeloid cells induced by exposure to doxorubicin, etoposide and hydrogen peroxide. Blood, 88: 1805, 1996.
6. Wright, J. A., Smith, H. S., Wat, F. M., Hancock, M. C., Hudson, D. L. and Stark, G. R.: DNA amplification is rare in normal human cells. Proc. Natl. Acad. Sci. USA, 87: 1791, 1990.
7. Tlsty, T. D.: Normal diploid human and rodent cells lack a detectable frequency of gene amplification. Proc. Natl. Acad. Sci. USA, 87: 3132, 1990.
8. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C. and Wahl, G. M.: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937, 1992.
9. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T. and Tlsty, T. D.: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923, 1992.
10. Groker, E., Waltham, M., Kheradpour, A., Trippett, T., Mazumdar, M., Elisseyeff, Y., Schnieders, B., Steinherz, P., Tan, C., Herman, E. and Bertino, J. R.: Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood, 86: 677, 1995.
11. Shinohara, N., Libert, M., Wedemeyer, G., Chang, J. H. C. and Grossman, H. B.: Evaluation of multiple drug resistance in human bladder cancer cell lines. J. Urol., 150: 505, 1993.
12. Stone, S., Dayananth, P. and Kamb, A.: Reversible, p16 mediated cell cycle arrest as a protection from chemotherapy. Cancer Res., 56: 3199, 1996.
13. Reznikoff, C. A., Belair, C. D., Yeager, T. R., Savelieva, E., Blelloch, R. H., Puthenveettil, J. A. and Cuthill, S.: A molecular model of human bladder cancer pathogenesis. Semin. Oncol., 23: 571, 1996.
14. Sharma, R. C. and Shimke, R. T.: The propensity for gene amplification: a comparison of protocols, cell lines, and selection agents. Mut. Res., 304: 243, 1994.
15. Reznikoff, C., Belair, C., Savelieva, E., Zhai, Y., Pfeifer, K., Yeager, T., Thompson, K. J., DeVries, S., Bindley, C., Newton, M. A., Sekhon, G. and Waldman, F.: Long-term genomic stability and minimal genotypic and phenotypic alterations on HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes & Dev., 8: 2227, 1994.
16. Reznikoff, C. A., Loretz, L. J., Pesciotta, T. D., Oberley, T. D. and Ignjatovic, M. M.: Growth kinetics and differentiation in vitro of normal uroepithelial cells on collagen gel substrates in defined medium. J. Cell. Physiol., 131: 285, 1987.
17. Assarif, Y. G. and Shimke, R. T.: Identification of methotrexate transport deficiency in mammalian cells using fluoresceniated methotrexate and flow cytometry. Proc. Natl. Acad. Sci. USA, 84: 7154, 1987.
18. Cooper, M. J., Haluschak, J. J., Johnson, D., Schwartz, S., Morrison, L. J., Lippa, M., Hatzivassiliou, G. and Tan, J.: p53 mutations in bladder cancer cell lines. Oncology Res., 6: 569, 1994.
19. Yeager, T., Stadler, W., Belair, C., Puthenveettil, J., Olopade, O. and Reznikoff, C.: Increased p16 levels correlates with pRb alterations in human urothelial cells. Cancer Res., 55: 493, 1995.
20. Reznikoff, C. A., Yeager, T. R., Belair, C. D., Savelieva, E., Puthenveettil, J. A. and Stadler, W. M.: Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7 transformed human uroepithelial cells. Cancer Res., 56: 2886, 1996.
21. Yeager, T. R., DeVries, S., Jarrard, D. F., Nakada, S. Y., Kao, C., Moon, T. D., Bruskewitz, R., Stadler, W. M., Meisner, L. F., Gilchrist, K. W., Newton, M. A., Waldamn, F. M. and Reznikoff, C. R.: Overcoming cellular senescence in human cancer pathogenesis. Genes & Dev. (In Press).